THE USE OF GROWTH FACTORS CAN IMPROVE RESULTS OF ANTIVIRAL THERAPY IN PTS WITH RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION (LTX)

2010 ◽  
Vol 90 ◽  
pp. 855
Author(s):  
M. S. Hubutiya ◽  
V. E. Syutkin ◽  
A. A. Salienko ◽  
O. I. Andreytzeva ◽  
A. V. Chzhao
Keyword(s):  
Liver Transplantation ◽  
Growth Factors ◽  
Antiviral Therapy ◽  
Hcv Infection

scholarly journals Experience of effective antiviral therapy in a liver recipient with recurrent HCV infection genotype 1

2019 ◽  
Vol 20 (4) ◽  
pp. 54-60
Author(s):  
D. V. Umrik ◽  
O. M. Tsiroulnikova ◽  
I. A. Miloserdov ◽  
R. A. Latypov ◽  
E. T. Egorova
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Antiviral Therapy ◽  
Liver Diseases ◽  
Hcv Infection ◽  
Rapid Progression ◽  
Genotype 1 ◽  
Wide Range ◽  
Common Causes ◽  
Before And After

HCV infection is one of the most common causes leading to the development of terminal liver diseases – cirrhosis and hepatocellular carcinoma, the main treatment for which is orthotopic liver transplantation. However, with continued virus replication, 100% reinfection occurs, which leads to the rapid progression of cirrhosis of the graft and the loss of its function. Standard interferon-containing therapy is ineffective for HCV infection, especially genotype 1, both before and after transplantation, and also has a wide range of adverse events. The article presents the successful experience of treating the recurrence of HCV infection 1 genotype in a patient who underwent liver transplantation and several courses of ineffective antiviral therapy.

scholarly journals Antiviral therapy of hepatitis C with 1 genotype after liver transplantation

2018 ◽  
Vol 20 (3) ◽  
pp. 105-115
Author(s):  
O. M. Tsiroulnikova ◽  
D. V. Umrik
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Immunosuppressive Therapy ◽  
Developed Countries ◽  
Hcv Infection ◽  
Standard Interferon ◽  
Poor Tolerance ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Chronic HCV infection is the leading cause of liver transplantation in adults in developed countries. Unfortunately, the reinfection of the graft inevitably occurs in  all patients with persistent replication of the virus. Against the background of the  necessary immunosuppressive therapy, the progression of the disease accelerates,  leading to rapid decompensation of the liver. Antiviral therapy significantly improves  the results of transplantation, but the use of standard interferon-based  regimens is associated with low efficacy (no more than 30% for the most common 1  genotype of the virus) and poor tolerance. The article describes new interferon- free oral regimens used to treat the recurrence of HCV infection of 1 genotype.

Sign in / Sign up

Export Citation Format

Share Document